<DOC>
	<DOCNO>NCT00892385</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methoxyamine temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving methoxyamine together temozolomide may kill tumor cell . PURPOSE : This phase I trial study side effect best dose methoxyamine give together temozolomide treat patient advance solid tumor .</brief_summary>
	<brief_title>Methoxyamine Temozolomide Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose methoxyamine give conjunction temozolomide patient without CNS disease . - To determine dose limit toxicity combination methoxyamine temozolomide patient without CNS disease . - To determine pharmacokinetics two agent give alone combination , well pharmacokinetic profile methoxyamine single one-hour IV administration . - To determine relative DNA damage , single double strand break comet assay blood mononuclear cell serve surrogate tumor response drug combination . OUTLINE : This dose escalation study methoxyamine . Patients receive oral temozolomide 5 day every 28 day methoxyamine IV 1 hour every 28 day . Methoxyamine IV administration follow , within 5 minute , initial administration TMZ day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Blood sample collect periodically correlative study . Samples analyze methoxyamine temozolomide pharmacokinetics , apurinic/apyrimidinic site , DNA strand break determination comet assay .</detailed_description>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must histologically confirm solid tumor consider incurable amenable conventional surgical , radiation therapy chemotherapy treatment program . Prior chemotherapy and/or radiation allow . At least 3 week must elapse since prior largefield radiation therapy ; patient must previous anticancer therapy least 3 week ( 6 week mitomycinC nitrosoureas ) ; recover treatment related toxicity &lt; grade 1 accord NCI CTCAE version 3.0 ( exception alopecia radiationinduced taste change ) . Prior temozolomide treatment restrict . ECOG performance status ( PS ) 02 ( Karnofsky PS 50100 % ) Life expectancy ≥ 12 week Patients must normal organ marrow function define : Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 10.0 g/dL Total bilirubin ≤ 1.5 mg/dL AST ≤ 2.5 time upper limit normal Creatinine ≤ 1.5 mg/dL and/or creatinine clearance ≥ 60 mL/min Patients know primary metastatic CNS disease , eligible participation cohort B , cohort A . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document . Patients may receive investigational agent receive investigational agent least 3 week . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant lactate woman exclude study methoxyamine temozolomide combination likely teratogenic . NYHA classification III IV heart disease Patients know primary metastatic CNS disease ( cohort B ) eligible mini mental status exam score &lt; 15 evidence leptomeningeal disease . Patients preexist neurologic toxicity &gt; grade1 ( per CTCAE , version 3.0 ) eligible participation cohort A . Patients screen participation cohort B preexist neurologic toxicity &gt; grade 2 ( per CTCAE , version 3.0 ) eligible , unless preexist neurologic toxicity document detail patient 's participation trial approve neurooncology team participate institution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>